Background
==========

Lung cancer has the highest mortality rate among all types of malignancies, accounting for approximately 29% of all cancer-related deaths in the United States \[[@B1]\]. It has been estimated that in 2006 alone, the number of new lung cancer cases will exceed 174,000 and approximately 163,000 people will die of this disease \[[@B1]\]. Tobacco smoking accounts for 85% of the lung cancers. Former heavy smokers remain at an elevated risk for developing lung cancer even years after they stop smoking \[[@B2],[@B3]\]. Fifty percent of newly diagnosed lung cancer patients are former smokers \[[@B4]\]. It is therefore important to understand the effects of tobacco smoking on the bronchial epithelium in both active and former smokers.

Recently, a large-scale microarray study characterized gene expression differences between current, former, and never smokers \[[@B5]\], and identified specific genes related to xenobiotic functions, anti-oxidation, cell adhesion and electron transport to be more highly expressed in current smokers relative to never smokers. Genetic regulators of inflammation and putative tumor suppressor genes exhibited decreased expression in current smokers relative to never smokers. Most significantly, a number of genes were identified that exhibited irreversible expression changes upon smoking cessation.

Additional reports have also identified increased expression of various xenobiotic metabolic enzymes including members of the cytochrome P450 (CYP) and glutathione S-transferase (GST) families of proteins in response to cigarette smoke exposure \[[@B5]-[@B10]\]. CYP enzymes mediate the conversion of *benzo (a) pyrene*and other polycyclic aromatic hydrocarbons (PAH) to carcinogenic intermediates that interact with genomic DNA \[[@B8]\], thus contributing to the formation of DNA adducts in smokers \[[@B11]-[@B13]\]. Members from both of the *CYP*and *GST*gene families have been implicated as potential susceptibility loci mediated by the presence of single nucleotide polymorphisms (SNPs) leading to aberrant expression in response to smoking \[[@B14],[@B15]\].

Another important process associated with tobacco smoke exposure is the airway mucosal response. In animal models, it has been shown that exposure to cigarette smoke induces goblet cell hyperplasia with accompanied mucus production \[[@B16],[@B17]\]. Moreover, mucin 5 (MUC5AC), has been shown to be the most highly expressed mucin in bronchial secretions \[[@B18]\], induced in response to cigarette smoke through an EGFR-dependent mechanism \[[@B19]\]. However, beyond this, little is known of the genes that are associated with airway remodeling as a result of tobacco smoking.

Serial analysis of gene expression (SAGE) is a quantitative experimental procedure widely used to determine expression profiles through the enumeration of short sequence tags and their relative abundance \[[@B20]\]. Although the construction and sequencing of an individual SAGE library is expensive and laborious compared to microarray analysis, SAGE offers the invaluable potential for gene discovery as the analysis is not limited to genes represented on an array. Moreover, comparisons between independent experiments can be performed without sophisticated normalization \[[@B21],[@B22]\].

In this study, we compare the bronchial epithelial transcriptomes of current, former, and never smokers to determine the effect of active smoking on gene expression using bronchial brushings from the peripheral sub-segmental airways. Genes whose expression is reversible upon smoking cessation are expected to differ in abundance between current and former smokers, but are similar between former and never smokers. Conversely, gene expression that is irreversible upon smoking cessation will show similar levels in current and former (ever) smokers but differ between ever and never smokers. Here, we focus on identifying both reversible and irreversible gene expression changes and specifically consider these expression changes in the context of airway mucosal response, and susceptibility to cancer development.

Results and Discussion
======================

SAGE library statistics
-----------------------

Twenty-four SAGE libraries were constructed from bronchial epithelial specimens acquired from eight current smokers, twelve former smokers and four never smokers (Table [1](#T1){ref-type="table"}). A former smoker was defined as someone who had stopped smoking for one year or longer. The smoking status was verified using exhaled carbon monoxide monitoring. Raw SAGE data for these transcriptomes has been made publicly available at National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) with series accession number GSE5473. From these 24 libraries, we have collectively sequenced 3,111,471 SAGE tags, yielding 231,866 unique tags, making this the largest human SAGE study reported to date (Figure [1A](#F1){ref-type="fig"}). Of the unique tags, nearly half were present in more than one library at a tag count of one or greater, and 70% (82,983 tags) of these tags map to a *UniGene*cluster. As multiple tags frequently map to the same *UniGene*cluster, 25,653 unique *UniGene*clusters are represented in our dataset. Significantly, over 27,000 tags did not map to existing annotated genes, reiterating the continuing potential of re-mining this large dataset as tag-to-gene mapping improves with the continuing annotation of human transcripts.

![(A) SAGE library statistics: Summary statistics of the 24 SAGE libraries analyzed in this study. Mapping information was based on the May 10th, 2006 version of *SAGEGenie*\[45\]. In total, over 3,000,000 SAGE tags were sequenced, with over 110,000 unique tags represented upon the exclusion of super singleton tags. (Super singleton tags are tags which have a count of 1 in a single library only). Approximately 75 % of these 110,000 unique tags, (potentially representing as many unique transcripts), mapped to an annotated *UniGene*cluster. As multiple SAGE tags frequently map to the same *UniGene*cluster, we have identified at a total of 25,653 distinct *UniGene*clusters within our dataset, approximately 68% of which represent previously characterized genes. Notably, 25% of the unique tags had no mapping, suggesting much information is currently unknown. (B) Transcriptome Venn diagram: Venn diagram of the transcriptomes of current, former and never smokers. Reported is the number of tags which are expressed in every library group at a raw tag count greater than or equal to 2, representing the tags which are constitutively expressed in each set. Nearly 2000 SAGE tags, mapping to over 1700 genes are common to all 24 SAGE libraries. A lower number of never smokers may have contributed to a higher number of preferentially expressed transcripts in this group.](1471-2164-8-297-1){#F1}

###### 

Demographics of subjects in study

  **Sample Name**   **Gender**   **Age at Analysis**   **Pack-Years**   **Smoking Status\***   **Years of smoking cessation (years)**   **Lung function (predicted FEV~1~%)**   **Name from previous study\*\***
  ----------------- ------------ --------------------- ---------------- ---------------------- ---------------------------------------- --------------------------------------- ----------------------------------
  Current 1         F            63                    40               CS                     N/A                                      69                                      BE-13
  Current 2         M            56                    62               CS                     N/A                                      89                                      BE-7
  Current 3         F            63                    44               CS                     N/A                                      96                                      BE-12
  Current 4         M            68                    81               CS                     N/A                                      76                                      BE-1
  Current 5         M            64                    45               CS                     N/A                                      73                                      BE-2
  Current 6         M            66                    53               CS                     N/A                                      85                                      \-
  Current 7         M            52                    48.1             CS                     N/A                                      63                                      \-
  Current 8         F            55                    34.4             CS                     N/A                                      81                                      \-
  Former 1          M            68                    33               FS                     19                                       50                                      BE-3
  Former 2          M            69                    100              FS                     1                                        21                                      BE-4A/4B
  Former 3          M            68                    30               FS                     1                                        30                                      BE-9
  Former 4          M            70                    75               FS                     17                                       76                                      BE-5
  Former 5          M            67                    55               FS                     5                                        N/A                                     BE-6
  Former 6          M            65                    82               FS                     10                                       59                                      BE-10
  Former 7          F            56                    64               FS                     1.5                                      71                                      BE-11A
  Former 8          F            63                    45               FS                     4.5                                      83                                      BE-14
  Former 9          M            72                    40               FS                     32                                       87                                      BE-15
  Former 10         F            71                    56               FS                     16                                       58                                      BE-16
  Former 11         M            72                    63               FS                     6                                        N/A                                     BE-8B
  Former 12         M            69                    55.3             FS                     21                                       57                                      \-
  Never 1           M            58                    0                NS                     N/A                                      115                                     \-
  Never 2           F            56                    0                NS                     N/A                                      104                                     \-
  Never 3           M            53                    0                NS                     N/A                                      N/A                                     \-
  Never 4           F            81                    0                NS                     N/A                                      N/A                                     \-

\* CS = Current Smoker, FS = Former Smoker, NS = Never Smoker

\*\*Subset of samples were used in a previous study by Lonergan *et al*2006 \[55\]

Analysis of the current, former and never smoker transcriptomes
---------------------------------------------------------------

We determined both the number of SAGE tags present in each of the current, former and never smoker transcriptomes, as well as those tags equally represented among the three different datasets. The criteria chosen for preferential expression was a threshold of a raw tag count of ≥ 2 across all samples in a particular set, but not existing in the other sets. Out of 3,033 tags expressed in all current smokers, we found 227 preferentially expressed tags (Additional file [1](#S1){ref-type="supplementary-material"}). In former smokers, 102 tags were found to be preferentially expressed (out of 2,579 tags) (Additional file [2](#S2){ref-type="supplementary-material"}), and in never smokers, 2,013 tags were found to be preferentially expressed (out of 5,192) (Additional file [3](#S3){ref-type="supplementary-material"}). It should be noted that the number of tags preferential to the never smoker set is substantially higher, most likely due to the lower sample size of never smokers relative to the other two groups. However, since we are using never smokers as a reference, a larger transcriptome will lessen the likelihood that we would find transcripts that are preferentially expressed in current and former smokers that were not correct. Looking at those tags which are common to all three groups, it was found that 1,970 tags (mapping to 1,733 unique genes) were expressed in all 24 libraries (Additional file [4](#S4){ref-type="supplementary-material"}). A Venn diagram illustrating the expression patterns of these three groups is given in Figure [1B](#F1){ref-type="fig"}.

Genes differentially expressed between current and never smokers
----------------------------------------------------------------

We used a Mann Whitney U test to identify tags differentially expressed in the transcriptomes of current and never smokers. Using cut-off requirements of *p*≤ 0.05, and a fold change of the means ≥ 2, we identified 609 SAGE tags (mapping to 487 unique genes) to be differentially expressed between current and never smokers (Additional file [5](#S5){ref-type="supplementary-material"}).

Supervised clustering and principal component analysis (PCA) of current, former and never smokers
-------------------------------------------------------------------------------------------------

Using the 609 tags found to be differentially expressed between current and never smokers (Additional file [5](#S5){ref-type="supplementary-material"}), single link hierarchical clustering was performed using the program *Genesis*\[[@B23]\]. We hypothesized that these 609 tags would classify current, former and never smokers. Indeed, distinct clusters emerged separating groups of current and former smokers with one exception of Current4 (Figure [2A](#F2){ref-type="fig"}). Of note, the former smoker who ceased smoking for only one year (Former 2) clustered with other former smokers. Moreover, principal component analysis (PCA) further validates the distinct groups of current, former and never smokers (Figure [2B](#F2){ref-type="fig"}).

![(A) Cluster analysis of current, former and never smokers: Single link hierarchical clustering using the 609 SAGE tags comprised in Additional file [5](#S5){ref-type="supplementary-material"} representing tags differentially expressed between current and never smokers. Distance measure used was a Euclidean distance. The visualization package *Genesis*\[23\] was used for clustering. Green rectangles represent samples with lower expression for the particular gene amongst the samples, and red rectangles represent samples where the gene is highly expressed relative to other samples. (B) Principal component analysis of current, former and never smokers. Expression values used were scaled to tags per million (TPM). Each tag was then normalized by dividing its value by the maximum value for that tag seen in all the libraries. Subsequently, this value was then multiplied by 6 and then subtracted by 3 to put the values ratios in the range of -3 to 3. A co-variance based approach was used and the statistics toolbox in *MatLab*(Mathworks) was used. Current smokers are represented in red, former smokers are represented in blue and never smokers are represented in green.](1471-2164-8-297-2){#F2}

Reversible gene expression changes upon cessation of smoking
------------------------------------------------------------

To determine reversibility of smoking-related gene expression changes, we intersected tags differentially expressed between current and never smokers against tags showing significant expression difference between current and former smokers using similar criteria. By comparing these two sets, we can deduce which gene expressions are reversible, i.e., which genes are largely influenced by active smoking. This analysis yielded 161 tags mapping to 121 unique genes, which were deemed statistically significant, and representing 26% of the total number of differentially expressed tags between current and never smokers (Figure [3A](#F3){ref-type="fig"}, Additional file [6](#S6){ref-type="supplementary-material"}). Further analysis of these 121 differentially expressed genes has identified two main functions: xenobiotic metabolism and nucleotide metabolism (representing 33% of the reversible gene expression changes) (Table [2](#T2){ref-type="table"}) and airway mucus secretion (representing 12% of the reversible gene expression changes) (Table [3](#T3){ref-type="table"}). Genes related to oxidative stress were considered as part of the xenobiotic metabolism/nucleic acid metabolism category, and those genes previously associated with xenobiotic metabolism and oxidative stress through smoke exposure were among those identified \[[@B5],[@B24],[@B25]\].

![Principal component of current, former and never smokers using (A) the 161 tags deemed reversible upon smoking cessation (Additional file [6](#S6){ref-type="supplementary-material"}) and (B) the 152 tags deemed irreversible upon smoking cessation (Additional file [7](#S7){ref-type="supplementary-material"}). Expression values used were scaled to tags per million (TPM). Each tag was then normalized by dividing its value by the maximum value for that tag seen in all the libraries. Subsequently, this value was then multiplied by 6 and then subtracted by 3 to put the values in the range of -3 to 3. A co-variance based approach was used and the statistics toolbox in *MatLab*(Mathworks) was used. Current smokers are represented in red, former smokers are represented in blue and never smokers are represented in green.](1471-2164-8-297-3){#F3}

###### 

Reversible gene expression upon smoking cessation related to xenobiotic metabolism and DNA adduct formation (genes in bold have not been previously associated with smoking)

  **Tag**              **Gene Symbol**   **Gene Name**                                                           **CS Mean\***   **FS Mean\***   **NS Mean\***   **P-Value (CVsF)**
  -------------------- ----------------- ----------------------------------------------------------------------- --------------- --------------- --------------- --------------------
  GGCCCAGGCC           ALDH3A1           Aldehyde dehydrogenase 3 family, memberA1                               4355            313             261             0.00002
  TTAAAAATTC           ADH7              Alcohol dehydrogenase 7 (class IV)                                      899             145             130             0.00002
  AGGTCTGCCA\*\*\*     AKR1C2            Aldo-keto reductase family 1, member C2                                 547             116             74              0.00002
  AATGCTTTTA           CYP1B1            Cytochrome P450, family 1, subfamily B, polypeptide 1                   204             13              0               0.00002
  **TTGGAATCCA**       **STAU2**         **Staufen, RNA binding protein, homolog 2 (Drosophila)**                **67**          **17**          **23**          **0.00002**
  TTATCAAATC           NQO1              NAD(P)H dehydrogenase, quinone 1                                        809             202             149             0.00003
  CAAATAAACC           PIR               Pirin (iron-binding nuclear protein)                                    260             47              43              0.00003
  GGCCCCATTT           CBR1              Carbonyl reductase 1                                                    144             31              24              0.00003
  TATTTTTGTT           TXNRD1            Thioredoxin reductase 1                                                 250             88              78              0.00006
  GGTGGTGTCT           GPX2              Glutathione peroxidase 2 (gastrointestinal)                             384             40              46              0.00011
  **TATTTTTGAA**       **DRB1**          **Developmentally regulated RNA-binding protein 1**                     **204**         **32**          **22**          **0.00011**
  **TGGGAGTGGG\*\***   **NMNAT2**        **Nicotinamide nucleotide adenylyltransferase 2**                       **175**         **17**          **9**           **0.00011**
  CAAGACCAGT           GSTA2             Glutathione S-transferase A2                                            1436            485             528             0.00019
  GCTTGAATAA           AKR1B10           Aldo-keto reductase family 1, member B10 (aldose reductase)             332             10              15              0.0003
  **GTGCAGGGAG**       **SPDEF**         **SAM pointed domain containing ets transcription factor**              **239**         **64**          **50**          **0.0003**
  **GGAGGCTTCC**       **MECR**          **Mitochondrial trans-2-enoyl-CoA reductase**                           **85**          **26**          **22**          **0.0003**
  GTGATGTAAG           SRXN1             Sulfiredoxin 1 homolog (S. cerevisiae)                                  63              14              11              0.0003
  **TATGCTTTAA**       **NT5DC1**        **5\'-nucleotidase domain containing 1**                                **59**          **23**          **24**          **0.0003**
  **GAACGCCTAA**       **DPYSL2**        **Dihydropyrimidinase-like 2**                                          **1**           **21**          **23**          **0.0004**
  TTTTCTGAAA           TXN               Thioredoxin                                                             698             326             212             0.00048
  CTTGCATAAG           CYP1A1            Cytochrome P450, family 1, subfamily A, polypeptide 1                   89              2               0               0.00048
  GCAAGAAGAG           ALDH3A1           Aldehyde dehydrogenase 3 family, memberA1                               77              10              2               0.00048
  AGAACAAAAC           PRDX1             Peroxiredoxin 1                                                         1043            418             510             0.00071
  **AAATATTTAA**       **SLC35A3**       **Solute carrier family 35, member A3**                                 **47**          **14**          **19**          **0.00071**
  CGGCTGAATT           PGD               Phosphogluconate dehydrogenase                                          252             104             80              0.00106
  **CTTATCAGTA**       **BTBD7**         **BTB (POZ) domain containing 7**                                       **94**          **22**          **2**           **0.00106**
  AAGAGTTTTG           AKR1B1            Aldo-keto reductase family 1, member B1 (aldose reductase)              25              5               6               0.00141
  GCTGAGATGA\*\*       CYP4F11           Cytochrome P450, family 4, subfamily F, polypeptide 11                  22              6               2               0.00141
  GGCGCCTCCT           TALDO1            Transaldolase 1                                                         232             76              94              0.00152
  **GACACAGCAA**       **ENTPD8**        **Ectonucleoside triphosphate diphosphohydrolase 8**                    **24**          **3**           **2**           **0.00159**
  **CAGTCTAAAA**       **UCHL1**         **Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)**   **92**          **4**           **0**           **0.00197**
  ACATCCTAGG           ALDH1A1           Aldehyde dehydrogenase 1 family, member A1                              60              28              30              0.00216
  TTAGAAGGAA           NQO1              NAD(P)H dehydrogenase, quinone 1                                        41              14              9               0.00216
  AGGTCTACCA           AKR1C2            Aldo-keto reductase family 1, member C2                                 270             32              8               0.00292
  ATTAGGCCTG           TXNRD1            Thioredoxin reductase 1                                                 51              19              17              0.00297
  GAGAGCTTTG           AKR1C3            Aldo-keto reductase family 1, member C3                                 149             21              22              0.00298
  TACGCTTGGT           CYB5R1            Cytochrome b5 reductase 1                                               68              32              30              0.00298
  CACTGCCTTG           FTH1              Ferritin, heavy polypeptide 1                                           59              23              17              0.00298
  CTGCTGCACT           GSR               Glutathione reductase                                                   126             54              50              0.0041
  **GGCAAAATTA**       **SLC35A3**       **Solute carrier family 35, member A3**                                 **73**          **32**          **35**          **0.0041**
  ACCTTGGGGT           NQO1              NAD(P)H dehydrogenase, quinone 1                                        73              19              6               0.0041
  **AATGTTCAGG**       **COQ6**          **Coenzyme Q6 homolog, monooxygenase (yeast)**                          **29**          **12**          **4**           **0.00708**
  **CACTGACCAG**       **NOD27**         **Nucleotide-binding oligomerization domains 27**                       **31**          **10**          **0**           **0.00927**
  **CTCGGAGGCC**       **SEPX1**         **Selenoprotein X, 1**                                                  **71**          **32**          **28**          **0.00956**
  **CTCCAAAAAA**       **CPSF2**         **Cleavage and polyadenylation specific factor 2, 100 kDa**             **118**         **44**          **14**          **0.02013**
  AATGGAAACT           GCLM              Glutamate-cysteine ligase, modifier subunit                             34              16              9               0.03186

**\***Mean in tags per million (TPM)

\*\* Changed mapping with *TAGMapper*\[56\]

\*\*\*Tag maps with equal reliability to *AKR1C1*

For example, *ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8)*, an extracellular nucleic acid metabolic enzyme, is among 18 novel genes (labeled in bold in Table [II](#T2){ref-type="table"}) not previously associated with smoking and whose expression is increased in response to active smoking. According to enzyme classification, *ENTPD8*is involved in purine and pyrimidine metabolism. Hence, this gene may potentially play a role in the chemical formation of DNA adducts.

Gene expression related to airway muco-ciliary function is also elevated in both current versus former smokers and current versus never smokers (Table [3](#T3){ref-type="table"}). For example, *trefoil factor 3*(*TFF3*), a structural component of mucus that is elevated in inflammatory response \[[@B26],[@B27]\], and *calcium binding tyrosine*-(*Y*) *phosphorylation regulated*(*CABYR*), originally shown to be localized in the principal part of the human sperm flagellum \[[@B28]\], are both highly expressed in current smokers relative to former and never smokers. Though *TFF3*was recently shown to be expressed in response to chronic exposure of nicotine in intestinal cells \[[@B29]\], this is the first report of this gene being overexpressed within the bronchial epithelium in response to active smoking. Based on its assumed role in sperm motility, *CABYR*may be involved in ciliary function associated with muco-ciliary clearance response within the lung \[[@B28]\]. Interestingly, overexpression of *CABYR*variants have been reported in a variety of brain tumors \[[@B30]\], suggesting a role in carcinogenesis. Previous observation of increased *MUC5AC*expression in current relative to never smokers and increased expression of *microseminoprotein, beta- (MSMB)*, a gene shown to be present in mucosal secretions \[[@B31]\], supports the possibility of induction of airway mucosal response in active smokers \[[@B5],[@B24],[@B25],[@B32]\].

###### 

Reversible gene expression upon smoking cessation related to mucus secretion (genes in bold have not been previously associated with smoking)

  **Tag**          **Gene Symbol**   **Gene Name**                                                **CS Mean\***   **FS Mean\***   **NS Mean\***   **P-Value (CVsF)**
  ---------------- ----------------- ------------------------------------------------------------ --------------- --------------- --------------- --------------------
  **GAATGAACTG**   **EDIL3**         **EGF-like repeats and discoidin I-like domains 3**          **72**          **5**           **8**           **0.00011**
  CTCCACCCGA       TFF3              Trefoil factor 3 (intestinal)                                4974            1978            1722            0.00019
  **GTGGAGAAGA**   **CLDN10**        **Claudin 10**                                               **89**          **23**          **26**          **0.00019**
  **GGAATTGCCC**   **BPIL1**         **Bactericidal/permeability-increasing protein-like 1**      **43**          **4**           **4**           **0.00029**
  TTGGTTTTTG       CXCL6             Chemokine (C-X-C motif) ligand 6                             147             414             371             0.0003
  CCTATCAGTA       MSMB              Microseminoprotein, beta-                                    15881           4405            2948            0.00048
  **CTTCCTGTGA**   **SBEM**          **Small breast epithelial mucin**                            **154**         **27**          **32**          **0.00071**
  **TGGAAATGTG**   **CBARA1**        **Calcium binding atopy-related autoantigen 1**              **49**          **18**          **15**          **0.00141**
  **CAAGCATAAA**   **CABYR**         **Calcium binding tyrosine-(Y)-phosphorylation regulated**   **63**          **4**           **4**           **0.00241**
  AGGGAGGCAG       SCGB1A1           Secretoglobin, family 1A, member 1                           135             473             436             0.0041
  TATCACATTC       CXCL6             Chemokine (C-X-C motif) ligand 6                             10              42              29              0.00573
  TTGCACCCTT       MSMB              Microseminoprotein, beta-                                    71              16              9               0.00735
  AGCTTAATGA\*\*   SCGB1A1           Secretoglobin, family 1A, member 1                           557             1478            3269            0.00956
  GAAAAAATAG       SCGB1A1           Secretoglobin, family 1A, member 1 (uteroglobin)             88              288             281             0.0124
  **GTGGCCACGG**   **S100A9**        **S100 calcium binding protein A9 (calgranulin B)**          **26**          **101**         **63**          **0.0124**
  **AAAATGTATT**   **CAV2**          **Caveolin 2**                                               **20**          **6**           **4**           **0.0144**
  GACAAGGATG       CX3CL1            Chemokine (C-X3-C motif) ligand 1                            29              63              93              0.01586

**\***Mean in tags per million (TPM)

\*\* Changed mapping with *TAGMapper*\[56\]

Irreversible gene expression changes upon cessation of smoking
--------------------------------------------------------------

By intersecting genes which are differentially expressed between current and never smokers with those that are different between former and never smokers, we can identify irreversible gene expression changes upon smoking cessation. This analysis yielded 152 tags (124 unique genes) meeting the criteria of statistical significance (*p*≤ 0.05) at a fold change ≥ 2 (Figure [3B](#F3){ref-type="fig"}, Additional file [7](#S7){ref-type="supplementary-material"}). Although genes identified by this analysis appear to be functionally diverse, a small number of genes related to the cell cycle process and DNA repair have been identified here. For example, expression of *P21/Cdc42/Rac1-activated kinase 1 (PAK1)*, *cyclin D1 (CCND1)*, and *cyclin G2 (CCNG2)*all appear to be irreversibly lower in ever (former and current) smokers relative to never smokers. This finding is consistent with a previous report of increased inhibition of cell proliferation through genes such as *CDKN1A*in a higher stage (GOLD-2) of chronic obstructive pulmonary disease (COPD) versus the lowest stage (GOLD-0) \[[@B33]\].

We also found genes associated with DNA repair to be differentially expressed between current and never smokers, but similar between current and former smokers. *APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1)*, *High-mobility group box 1 (HMGB1), REV1-like (REV1L)*, and *Tumor suppressor candidate 4 (TUSC4)*are repair genes which we have found to be irreversibly under-expressed in ever smokers. Significantly, *APEX1*has been shown to harbor SNPs associated with lung cancer susceptibility \[[@B34]\]. Moreover, *REV1L*is involved with the recruitment of DNA polymerase eta to assist in DNA replication at arrested replication forks in areas of DNA lesions such as those formed by thymine dimmers \[[@B35],[@B36]\]. *TUSC4*, also known as *NPRL2*, has recently been shown to increase sensitivity to cisplatin \[[@B37]\]. Finally, *HMGB1*has also been suggested to be involved with the recruitment of other repair-related proteins \[[@B38]\].

It should be noted that a significant proportion of former smokers in our sample set exhibited low FEV~1~levels, raising the possibility that airflow obstruction may be a confounding issue in this analysis. To address this, we used the 20 individuals with available FEV~1~data to compare individuals with moderate or severe COPD (FEV~1~\< 80%, n = 12) with those individuals that would be classified with at most mild COPD (FEV~1~≥ 80%, n = 8) according to the GOLD staging classification based on FEV~1~status \[[@B39],[@B40]\]. Of the 157 tags differentially expressed between these two groups, only 6 tags overlap with our list of irreversible genes (Additional file [8](#S8){ref-type="supplementary-material"}). This minimal overlap suggests that the irreversible genes identified are not significantly associated with airway obstruction based on FEV~1~status. Nonetheless, airway obstruction should be considered in the interpretation of differential gene expression between current and former smokers.

A similar approach to that described here was undertaken by Spira *et al*. where the expression of 13 genes, including some putative oncogenes and tumor suppressor genes, was deemed irreversible upon cessation of smoking. However, none of these 13 genes overlapped with those identified in our study. This lack of overlap may reflect the differing locations from which the bronchial brushings were obtained as Spira *et al*\[[@B5]\] sampled from the right main bronchus whereas we have sampled peripheral sub-segmental airways.

It is interesting to note that *MUC5AC*appears in both the lists of statistically reversible and irreversible gene expression changes suggesting that expression of this gene exhibits distinct states of expression among current, former and never smokers. Moreover, it should also be noted that although 311 of the 609 tags were classified as either reversible or irreversible, the remaining 298 tags did not meet the statistical criteria for either category.

Validation of select gene expression changes using quantitative RT-PCR
----------------------------------------------------------------------

In addition to the SAGE analysis, which identified genes associated with airway mucosal response and xenobiotic/nucleic acid metabolism as distinguishing features between current and former smokers, we have performed quantitative RT-PCR on a secondary cohort of current, former and never smokers to validate selected genes for expression changes (Additional file [9](#S9){ref-type="supplementary-material"}). In total, five genes were selected for validation. From the set of reversible genes, we have chosen *CABYR*, *ENTPD8*, and *TFF3*because their expression has not been associated with smoking previously. In addition, from the irreversible genes, we have selected *MUC5AC*. Using the delta-delta-Ct method to derive expression values, we then employed a Mann Whitney U Test to determine significance. The pattern of reversible over-expression in current smokers for *CABYR*, *ENTPD8*, and *TFF3*(Figure [4A](#F4){ref-type="fig"}) and the irreversible over-expression of *MUC5AC*(Figure [4B](#F4){ref-type="fig"}) observed from the SAGE data, was validated by quantitative RT-PCR (Additional file [10](#S10){ref-type="supplementary-material"}). Raw cycle thresholds for each gene are available in Additional file [9](#S9){ref-type="supplementary-material"}.

![SAGE and quantitative PCR (qRT-PCR) analysis of select genes: (A) Genes found to have reversible expression upon smoking cessation. Box plots of SAGE data and histograms for qRT-PCR for *CABYR, ENTPD8*and *TFF3*. Distribution of ratios between both current vs. former and current vs. former and never (Additional file IV) were found to be statistically different. (B) Genes found to be either partially or fully irreversible. Box plots of SAGE data and histograms for qRT-PCR for *MUC5AC*and *GSK3B*. Distribution of ratios between current vs. former and former vs. never were statistically different for *MUC5AC*and in addition, *GSK3B*was statistically significant for the combination of current and former vs. never. Box plot analysis was done using the Statistics toolbox from the *MathWorks MatLab*program. Red lines in the boxes represent the median expression value in terms of tags per million (TPM), and red \"plus\" signs represent outliers (values which are greater than 1.5 times the maximum value). The bottom and top part of the boxes represent the 2^nd^and 3^rd^quartiles of the data respectively. The error bars represent the 5^th^and 95^th^percentiles of the data. Quantitative RT-PCR validation was performed on a second cohort of nine current smokers, seven former smokers and six never smokers. Plotted is the average expression ratio relative to the average expression in never smokers of current (red), former (blue) and never (green) smokers. Statistical significance was determined using a one-tailed p-value from the Mann Whitney U Test (Supplemental Table IX).](1471-2164-8-297-4){#F4}

Airway epithelium response genes and their role in inflammation and cancer
--------------------------------------------------------------------------

Although the role of xenobiotic metabolism in smoking-induced carcinogenesis has been well documented \[[@B9],[@B15]\], the potential influence mediated by changes in the composition of the airway mucosa in the development of lung cancer, has not been thoroughly investigated. It is possible that constant dysregulation of expression of genes associated with mucus secretion (such as *TFF3*and *MUC5AC*) by smoking could potentially have a direct or indirect role in smoking-induced carcinogenesis.

One of the many genes involved in lung cancer development is *cyclooxygenase 2 (COX2)*, which plays a multi-faceted role in cellular proliferation, migration and invasiveness \[[@B41]\]. Notably, secretoglobin, family 1A, member 1 (SCGB1A1) protein has been shown to inhibit *COX2*at the mRNA level \[[@B42],[@B43]\]. We observed that *SCGB1A1*expression is drastically reduced in current smokers but is expressed at similar levels in former and never smokers, and a previous study showed decreased serum *SCGB1A1*level in smokers \[[@B44]\]. It should also be noted that none of the SAGE sequence tags identified in the analysis mapping to *SCGB1A1*are the most reliable tag according to *SAGE Genie*\[[@B45]\]. However, even though the most reliable tag to this gene, CTTTGAGTCC did not pass statistically, the trend of reduced expression in current smokers relative to former smokers and similar expression between former and never smokers is consistent with the sequence tags that did appear in the analysis. Moreover, given that multiple tags have appeared from our analysis, although not as reliably mapped, we are confident that we are detecting *SCGB1A1*mRNA expression. Interestingly, *COX2*mRNA expression was not detected in the bronchial epithelium of current, former and never smokers from our SAGE data. A recent report demonstrated a significant increase in *COX2*expression in normal lung fibroblasts when exposed to cigarette smoke extracts \[[@B46]\]. It is possible that *SCGB1A1*involvement is in the stroma and not in epithelial cells.

Despite lack of knowledge about *CABYR*, one of its few known interactions occurs with *GSK3B*\[[@B30]\].*CABYR*is a substrate of *GSK3B*\[[@B30]\], and exhibits reversible, increased expression with active smoking (Figure [4A](#F4){ref-type="fig"}). Though *GSK3B*was not identified as a smoking-related gene in our primary analysis, investigation of the SAGE data revealed a trend of similar decreased expression in current and former smokers relative to never smokers. Moreover, quantitative RT-PCR using a secondary cohort of samples validated that *GSK3B*expression is irreversibly reduced in ever smokers (Figure [4B](#F4){ref-type="fig"}). Recently, a published report using porcine tracheobronchial epithelial cells exposed to cigarette smoke components *in vitro*, demonstrated an inhibition of *GSK3B*gene expression \[[@B47]\]. *GSK3B*has been shown to negatively interact with *COX2*\[[@B48]\]. Reduced expression of *GSK3B*may therefore account for exaggerated inflammatory response despite smoking cessation and may contribute to development of lung cancer.

In this study, we have demonstrated differential expression of various components of respiratory tract mucus (including *TFF3*and *MUC5AC*) according to smoking status (Table [3](#T3){ref-type="table"}). However, our data indicates that *MUC5AC*expression is not completely reversible upon smoking cessation and in fact, exhibits three statistically distinct levels of expression between current, former and never smokers (Figure [4B](#F4){ref-type="fig"}). *TFF2*, a related motogen to *TFF3*, in conjunction with *epidermal growth factor (EGF)*, has been shown to promote airway restitution, (i.e., movement of neighboring airway epithelial cells in response to injury mimicking rapid epithelium regeneration), through the activation of the *epidermal growth factor receptor (EGFR)*\[[@B49]\], expressed in the normal bronchial mucosa \[[@B50],[@B51]\]. Other studies have also demonstrated increased expression of *MUC5AC*, along with *EGFR*and *v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3)*in active smokers \[[@B26],[@B32]\]. We examined *EGFR*expression in relation to smoking and found that there was a modest increase of approximately 1.5-fold between current and former smokers in our SAGE data. As enhanced expression of *EGFR*is well documented in lung cancer \[[@B52],[@B53]\], these results imply that enhanced expression of *TFF3*(and perhaps other genes associated with airway epithelial response and mucus secretion) may promote airway restitution in response to active smoking and that constant induction of airway reconstruction may play a role in the development of lung cancer (Figure [5](#F5){ref-type="fig"}).

![Expression trends of specific genes related to muco-ciliary function and airway restitution as compared with smoking status and lung cancer: *TFF3, CABYR*, and *MUC5AC*are over expressed in current smokers with lowered expression in both former and never smokers. Conversely, *SCGB1A1*shows the opposite effect, with lowered expression in current smokers as compared to former and never smokers. *MUC5AC*and *TFF3*are known to be components of mucus. *EGFR*levels are positively correlated with smoking status, with modestly higher levels in current smokers. *MUC5AC*and EGF have been shown to interact with *EGFR*in the process of airway restitution and *SCGB1A1*has been shown to decrease levels of *cyclooxygenase 2 (COX2)*in cancer cells. Interestingly, within this process alone, we see reversible *(TFF3*, *CABYR)*, partially reversible *(MUC5AC)*and completely irreversible *(GSK3B)*expression changes upon smoking cessation. Values refer to tag counts as tags-per-million (TPM).](1471-2164-8-297-5){#F5}

Conclusion
==========

This study represents the largest human SAGE study reported to date. Over three million SAGE tags were sequenced, representing over 110 thousand potentially unique transcripts expressed within the bronchial epithelium relative to cigarette smoke exposure. These libraries provide a valuable resource for future data mining. Based on the gene expression profiles of 24 current, former and never smokers, we identified both reversible and irreversible gene expression changes upon smoking cessation. Specifically, amongst those genes reversibly expressed, three main functions were identified: xenobiotic metabolism, nucleotide metabolism, and mucus secretion. In addition, some of the genes associated with airway mucosal response are strongly involved with airway epithelium repair and regeneration. Interestingly, investigating airway repair and regeneration revealed genes varying in the degree of reversibility, including those completely reversible (*TFF3*, *CABYR*), partially reversible (*MUC5AC*) and irreversible (*GSK3B*) expression changes upon smoking cessation. We have validated the SAGE expression data for *TFF3*, *CABYR*, *MUC5AC*, *GSK3B*and *ENTPD8*using a secondary cohort of current, former and never smokers. This is the first study demonstrating smoking-induced expression changes for this particular set of genes and importantly, it is the first time partial reversibility (*MUC5AC*) and irreversibility (*GSK3B*) and has been demonstrated using two different cohorts of samples with two independent assays for expression quantification. By comprehensively identifying gene expression changes that are reversible upon smoking cessation, we have introduced genes which may in future studies be investigated for polymorphisms, as those genes which are not sufficiently induced in response to smoking may identify candidate loci of susceptibility. Similarly, those genes and functions which do not revert to normal levels upon smoking cessation may also provide insight into why former smokers still maintain a risk of developing lung cancer.

Methods
=======

Specimen collection
-------------------

Bronchial epithelial cells were collected by bronchial brushings from 24 subjects -- 9 current smokers, 11 former smokers and 4 never smokers summarized in Table [1](#T1){ref-type="table"} -- by bronchial brushing as described previously \[[@B54],[@B55]\]. The subjects were volunteer smokers recruited from the community as part of a NCI-sponsored chemoprevention trial. The inclusion criteria were: age \> 45 years of age and a smoking history of ≥ 30 pack years. A former smoker was defined as one who had stopped smoking for at least one year or more. None of the subjects were on bronchodilator or inhaled steroids. The samples were obtained prior to treatment with an investigational chemoprevention agent.

Brushings were obtained from the peripheral airways using a 1.8 mm brush. A table of the basic demographics of the subjects used is listed in Table [1](#T1){ref-type="table"}.

Construction of SAGE libraries
------------------------------

To deduce the gene expression profiles, we used a method called serial analysis of gene expression (SAGE) which quantifies gene expression by the enumeration of transcript derived sequence tags \[[@B20]\]. SAGE libraries were constructed from each sample using the MicroSAGE protocol \[[@B55]\], and sequenced to a depth of \~150,000 SAGE tags per library. SAGE libraries were deposited in NCBI GEO with accession number GSE5473. Reproducibility of SAGE libraries obtained from the same bronchial brush was shown by our group previously. The R value between two libraries from the same lysate was 0.97 \[[@B55]\].

SAGE tag-to-gene mapping
------------------------

Tag-to-gene mapping was performed using a combination of the May 10^th^, 2006 build of *SAGEGenie*\[[@B45]\]. Tags with low reliability from *SAGEGenie*in Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} were also cross-referenced with *TagMapper*\[[@B56]\].

Statistical analysis of differentially expressed genes
------------------------------------------------------

Stringently, only tags which exhibited a mean tag count of ≥ 20 tags per million (TPM) in at least one of current, former or never smoker SAGE libraries were used in comparative analysis. For each specific comparison, in addition to the tag count requirement, a minimum fold change of the means of two was also required. The tag abundance requirement of a mean tag count of 20 TPM was used to filter the list of tags prior to statistical comparison to reduce the number of false positives. 8148 tags meet this criterion. Given the variability in smokers and limited sample size in this study, a non-parametric Mann Whitney U Test was used to determine if a given tag (representing a gene) was differentially expressed using a p-value threshold of p ≤ 0.05, unadjusted for multiple comparisons.

Validation of SAGE-specific targets using quantitative RT-PCR
-------------------------------------------------------------

Select targets identified in the SAGE study were validated using quantitative RT-PCR (qRT-PCR) in a second cohort of nine current, seven former and six never smokers. Briefly, 100 ng of RNA was isolated and converted to cDNA in a 50 μl reaction volume using the High-Capacity cDNA Archive Kit (cat \# 4322171, Applied Biosystems). 1 μl of the resulting cDNA was analysed by qPCR, with specified Taqman primers and TaqMan Universal PCR Master Mix (cat \# 4326708), using the iCycler iQTM Real-Time PCR Detection System (Bio-Rad). *CABYR*, *TFF3, MUC5AC, GSK3B*and *Actin Beta*were monitored for 40 cycles of PCR and *ENTPD8*for 50 cycles. Primers used for qRT-PCR are listed in Additional file [11](#S11){ref-type="supplementary-material"}.
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